Navigating Orphan GPCR Biology: High-Fidelity Reagents for Parkinson's Disease and Oncology Targets
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GPR37 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Full-Length Receptor | GPR37 Lentivirus Premade Particles. Codon-optimized ORF, CMV promoter, Puro resistance. For stable cell line generation preserving native conformation. | View GPR37 Products |
| Mutant Variants | GPR37 Disease-Associated Mutants (Recombinant). Lysine-free mutants for ubiquitination studies; Trafficking-deficient variants. Sequence Verified. | View GPR37 Products |
| Gene Delivery | GPR37 Promise-ORF. Full-length ORF for rational design and custom expression. | View GPR37 Products |
| Gene Silencing | GPR37 siRNA Set (3 unique sequences). For knockdown validation and specificity confirmation. HPLC purified. | View GPR37 Products |
| Detection | Anti-GPR37 Rabbit pAb. Synthetic peptide immunogen, affinity purified. Suitable for WB/IP. | View GPR37 Products |
| Benchmark Ab | Anti-GPR37 Control Antibody (Recombinant). Positive control for assay benchmarking. | View GPR37 Products |
| Related Target: GPR37L1 | GPR37L1 (PAEL-R Like Receptor). Homolog with 35% identity; Critical for off-target liability screening. | View GPR37L1 Products |
| Related Target: PARK2/PRKN | Parkin (PRKN) E3 Ligase. Essential pathway partner; governs GPR37 substrate degradation. | View PRKN Products |
| Related Target: PSAP | Prosaposin (PSAP). Endogenous neuroprotective ligand for GPR37; potential endogenous ligand candidate. | View PSAP Products |
Technical Specifications for Critical Assays
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Membrane Topology Preservation / GPCR Conformation | Full-length GPR37 Lentivirus with native signal peptide; HEK293 expression maintaining post-translational modifications. |
| Aggregation/Misfolding Detection | Wild-type vs. Trafficking-deficient mutant proteins; Non-reducing SDS-PAGE validation available. |
| Ubiquitination Site Mapping | Lysine-to-Arginine mutant panel; Defined K48/K63 linkage analysis substrates. |
| Cross-Reactivity with GPR37L1 | Ortholog and paralog proteins with <0.1% sequence cross-reactivity in antibody epitope regions; homolog panel for off-target selectivity assays. |
| ER Stress Induction Assays | High-purity (>95%) aggregates for toxicity studies; Endotoxin controlled (<1EU/µg). |
| Lack of Controls / False Positives | Recombinant positive control antibodies and validated siRNA included for reliable benchmarking and specificity checks. |
Live GPR37/Pael-R R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials
- Latest Neurodegeneration Research
- Latest Resistance Research
- Recent Patent Filings
Global Clinical Landscape & Future Outlook
The GPR37 target occupies a unique position at the intersection of neurodegeneration and oncology. Historically identified as Parkin-associated endothelin receptor-like receptor (PAEL-R), its accumulation in dopaminergic neurons characterizes autosomal recessive juvenile Parkinsonism. Current R&D focuses on two divergent strategies: Targeted Protein Degradation (TPD) approaches leveraging the endogenous Parkin-GPR37 axis, and oncogenic signaling inhibition in glioblastoma multiforme where GPR37 drives stemness. Meanwhile, the emerging Prosaposin (PSAP)-GPR37 axis has attracted intense interest for neuroprotective small molecule and peptide therapeutics. First-generation agonists and mimetics are reaching pre-clinical and early clinical validation, with the next wave targeting allosteric modulation and blood-brain barrier (BBB) penetrating modalities. The pipeline remains predominantly in preclinical/discovery phases, with no clinical-stage small molecules or biologics currently listed. The primary differentiation requirement centers on protein folding fidelity—misfolded GPR37 aggregates trigger ER stress, whereas properly trafficked receptor may signal through undefined G-protein coupling or act as a scavenger receptor.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Targeted Protein Degradation / PROTAC | Academic consortia, TPD biotechs, Parkin activator programs | Parkinson's Disease (PD), Neurodegeneration | Ubiquitination-competent full-length receptor; Parkin co-expression stable lines; Co-IP grade proteins. |
| Small Molecule Modulators (Agonists & Allosteric) | Academic consortia, Emerging CNS Biotechs, Orphan GPCR programs | PD, Neurodegeneration, Oncology (Glioma) | Calcium flux assays; cAMP modulation requires functional membrane expression (stable lentivirus cell lines). |
| Inhibitory mAbs | Neurodegeneration focused biotechs | PD, Glioblastoma | Cell surface binding (Flow cytometry validation); Internalization assays. |
| Peptide Mimetics | Prosaptide developers | Neuropathic Pain, Ischemia | Ligand binding assays (high-purity control receptors). |
| Bispecific mAbs (BBB-penetrating) | Large Pharma CNS Hubs | Neuro-oncology, PD | BBB-Crossing / Selectivity assay; Counter-screen against GPR37L1. |